ArticleLeukemia2020
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
F La Rosée et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
140 papers cite itlatest 60 shown
this paperpooled ittrialcites it